No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Todor Jeliaskov Appointed CEO of inHEART

Editor: What To Know

  • “At Elaia, we congratulate Todor Jeliaskov on his selection as Chief Executive Officer, we’re excited by the tremendous progress inHEART has made since Elaia’s investment in 2020 under Jean-Marc Peyrat’s leadership as CEO and would like to thank him and welcome him as the new Chief Technology Officer of the company,”.
  • “His proven leadership and experience perfectly complement our existing team to scale up the company and to support its ambition to be a major player in the double-digit growing market of cardiac electrophysiology.
  • He will lead the French company in its mission to bridge the gap between cardiology and medical imaging with a digital twin of the patient’s heart.

inHEART, the leader in image guidance for treatment of cardiac arrhythmias, has appointed Todor Jeliaskov as CEO. He will lead the French company in its mission to bridge the gap between cardiology and medical imaging with a digital twin of the patient’s heart. Todor Jeliaskov will work closely with co-founder and former CEO Jean-Marc Peyrat, who transitions to the role of CTO at inHEART.

“I am thrilled to welcome Todor as our new CEO,” said Jean-Marc Peyrat, co-founder of inHEART. “His proven leadership and experience perfectly complement our existing team to scale up the company and to support its ambition to be a major player in the double-digit growing market of cardiac electrophysiology.”

Todor Jeliaskov brings over 20 years of experience solving customers’ needs and generating returns for investors and shareholders at large, complex enterprises and startup organizations across continents and various industries. Before inHEART, Todor Jeliaskov was CEO of NuVera Medical, acquired by Biosense Webster (Johnson & Johnson) in November 2020. NuVera developed the next-generation of ultrasound imaging technology for cardiac interventions – 4D ICE. Todor Jeliaskov previously served as VP at GE Ultrasound, the worldwide market leader in diagnostic ultrasound. Todor Jeliaskov started his career at Siemens Medical Solutions. He holds a Ph.D. in Electrical Engineering and an MBA degree.

“I am honored to join the exceptionally talented inHEART team that developed a unique solution for the guidance of cardiac ablations. It is rare to see new technologies with such a substantial impact on patient care.” said Todor Jeliaskov. “I am excited to be part of this revolution and I look forward to driving its international deployment to make it accessible to most patients.”

“At Elaia, we congratulate Todor Jeliaskov on his selection as Chief Executive Officer, we’re excited by the tremendous progress inHEART has made since Elaia’s investment in 2020 under Jean-Marc Peyrat’s leadership as CEO and would like to thank him and welcome him as the new Chief Technology Officer of the company,” said Samantha Jérusalmy, Partner at Elaia. “We are confident that inHEART is poised for strong growth and Todor’s commercial leadership and management experience are unique assets in this new phase.” explains Sacha Loiseau, Venture Partner at Elaia.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy